A study published in the International Journal of Radiation Oncology*Biology*Physics demonstrates that clinicopathology (CP) based risk assessment frequently fails to accurately assess recurrence risk and radiation therapy benefit for patients diagnosed with DCIS (ductal carcinoma in situ). Consequently, treatment decisions based on CP alone may result in over 40% of women being over- or undertreated with radiation therapy when compared to the molecular-based test DCISionRT.
This article was originally published on MedicalXpress.com
